Top 10 Medical Stocks To Buy Right Now

Despite staggering increases in drug prices, Americans still aren’t living as long as those in other countries. And the worst part is they’re paying more, too…

One out of every four Americans reported that the cost of healthcare is their primary concern right now, according to a January 2017 Monmouth University poll. In fact, anxiety about paying medical bills now outpaces job and unemployment concerns, as well as worries about paying everyday household bills.

And it’s no wonder: In August, prices for medicine, doctor’s appointments, and health insurance rose at rates not seen since 1984.

Drug costs, in particular, are growing by double and triple digits each year. Back in October 2016, The Fiscal Times reported that specialty drug prices grew 18.9% and are projected to increase another 18.7% this year. Additionally, it reported that generic drug prices are expected to increase another 11% this year after already going up 11.3% in 2016.

Top 10 Medical Stocks To Buy Right Now: Envision Healthcare Holdings, Inc.(EVHC)

Advisors’ Opinion:

  • [By Paul Ausick]

    Envision Healthcare Corp. (NYSE: EVHC) dropped about 9.3% Tuesday to post a new 52-week low of $43.22 after closing Monday at $47.67. The 52-week high is $74.75. Volume of around 10 million shares traded was about six times the daily average. The company had no specific news.

  • [By Lisa Levin]

    Envision Healthcare Holdings Inc (NYSE: EVHC) shares shot up 211 percent to $70.15. Envision Healthcare and Amsurg Corp (NASDAQ: AMSG) reported the completion of their merger.

  • [By Ben Levisohn]

    Even on a day like today, somebody had to be the worst performer in the S&P 500, and today that somebody is Envision Healthcare (EVHC), which missed earnings forecasts last night.

Top 10 Medical Stocks To Buy Right Now: Nobilis Health Corp.(HLTH)

Advisors’ Opinion:

  • [By Monica Gerson]

    Nobilis Health Corp (NYSE: HLTH) is expected to report its quarterly earnings at $0.19 per share on revenue of $91.92 million.

    Avid Technology, Inc. (NASDAQ: AVID) is estimated to post its quarterly earnings at $0.36 per share on revenue of $144.02 million.

Top 10 Medical Stocks To Buy Right Now: iShares PHLX SOX Semiconductor Sector Index Fund(SOXX)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group giving investors and traders a bit of a roller-coaster ride while peerSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) really took off last year:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group under performingpeersSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX)will all taking offlast year:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group peaking in early 2015 while peerSTMicroelectronics NV (NYSE: STM) hasnt performed much better and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) have performed better:

  • [By Peter Graham]

    A long term performance chart shows Marvell Technology Group along with peersSTMicroelectronics NV (NYSE: STM) and ETF benchmarks SPDR S&P Semiconductor ETF (NYSEARCA: XSD) and iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX)all taking offlast year albeit MRVL has underperformed ETF benchmarks:

Top 10 Medical Stocks To Buy Right Now: Orion Marine Group Inc(ORN)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows small caps Great Lakes Dredge & Dock Corporation andLayne Christensen Company (NASDAQ: LAYN) underperforming, but possibly recovering while Orion Group Holdings (NYSE: ORN) had a clear reversal early last year:

Top 10 Medical Stocks To Buy Right Now: United Microelectronics Corporation(UMC)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    United Microelectronics (NYSE:UMC), for example, has said that it expects to begin “commercial production” of a 14-nanometer technology “by the second half of 2017,” per EETimes.

Top 10 Medical Stocks To Buy Right Now: Polo Ralph Lauren Corporation(RL)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Hanesbrands was just one of many retail companies that got shellacked this week. Under Armour (UAA) tumbled 29% after missing earnings forecasts and cutting its guidance, while Deckers Outdoor (DECK) plunged 21% after its earnings missed the Street consensus, and Ralph Lauren (RL) plummeted 13% after its CEO stepped down.

  • [By Casey Wilson]

    Ralph Lauren Corp. (NYSE: RL) just became the latest company to fall victim to the “Retail Ice Age.”

    The 50-year-old American icon announced it shuttered its flagship store at Fifth Avenue and 55th Street in New York City on Tuesday (April 4). It will also close 50 other retail locations by the end of the fiscal year.

  • [By Johanna Bennett]

    Times are tough for Ralph Lauren (RL). Profit and sales are fallingat theiconic clothingcompany, and investors who bet on a turnaround havelost their shirts on the stock. Adding to its troubles,CEO StefanLarsson is departingfollowing a creative clash with the companys namesake and founder.

    Pessimism, meanwhile, appears to be on the rise.

    According to a report by the financial analytics company S3 Partners, short interest in Ralph Lauren has risen since the start of the year, hitting historical levels. And while that short position is expected to keep expanding, bearish sentiments could turn on a dime.

    Ihor Dusaniwsky at S3 Partners writes:

    RL short interest levels, already at historical highs today, should continue to grow if the recent trend continues, but having made almost 23% in 2016 and 14% in 2017, short sellers may be quick to cover their positions and lock in profits if RLs stock price turns against them.

    Short interest in Ralph Lauren fell in 2016 as the stock price fella nd shorts covered positions, netting a return of 22.6%. So far this year, however, the short position as increased $226 million, or 38% to $815 million as of this morning, according to the S3 report.

    Its a profitable day for those short sellers. Todays 11% decline Ralph Laurens stock price on an $815 million short position has added $90 million to the short sellers collective bottom line.

    Ralph Lauren is down 11.5% in recent market actions to $77.26 a after earlier falling as low as $76.86 a share. Thats the lowest price for the stock since 2010.

Top 10 Medical Stocks To Buy Right Now: Fitbit, Inc.(FIT)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    With the benefit of hindsight, it’s clear that the better recent stock buy in the wearables space has been GPS device specialist Garmin (NASDAQ:GRMN) over former market darlingFitbit (NYSE:FIT). It turns out that Garmin’s diverse product line helped it weather collapsing sales in its core automotive division. Targeted innovation bets by Fitbit management, on the other hand, failed to hit the sweet spot of consumer demand amid rising competitive threats.

  • [By James E. Brumley]

    The rise and fall of Fitbit Inc (NYSE:FIT) – the company and the stock – was largely in step with an incredible buzz stemming from the introduction of the company’s wares followed by the revelation that the wrist-worn devices don’t always take accurate pulse rates. The whole matter has raised one overarching question….what will it take for any company to get cardiac monitoring wearables right? To that end, a couple of different articles on the issue of remote heart monitoring that are worth passing along.

  • [By Leo Sun]

    Many investors who watched Fitbit (NYSE:FIT) and GoPro (NASDAQ:GPRO) crash and burn may believe that demand for wearable devices — like fitness trackers and action cameras — is fading. Indeed, earlier estimates for these markets were far too bullish.

  • [By James E. Brumley]

    While the economy’s natural — and recurring — cycles favor different kinds of stocks at different times, not every great trend is necessarily a cyclical one. Sometimes, a trend is rooted in a technological development that changes cultural norms. The advent of the smartphone, for example, has made constant connectivity to the world around part of how we live our daily lives.

    These mega-trends present tremendous opportunities for investors too, provided they’re savvy enough to see them coming and play them the right way.

    One such mega-trend newly underway right now is the proliferation of wearables… devices that meld clothing (often a wrist-worn device) and technology to perform a function that couldn’t be performed otherwise. Much of the same technology that made the smartphone possible are now ushering in wearables.

    It’s not been a smooth beginning. however.

    While the buzz was strong and expectations reached a peak two years ago when Fitbit Inc (NYSE:FIT) was all the rage and in the wake of its IPO, the company’s growth wasn’t to be sustained. The company is struggling to muster any growth now, and FIT shares have fallen to a tenth of their value seen in late-2015, when the euphoria was strongest.

    Fitbit’s slowdown has been mirrored by other companies in the space. The wearables market only grew 3.1% in Q3 of 2016.

    On the flipside, while the debacle of Fitbit — the wearable industry’s iconic company — has been a painful, it’s also been a learning experience. And, it’s not as if the slowdown is unfurling without the wearables market never reaching a respectable size. International Data Corporation estimates were 23 million ‘wearables’ delivered in the third quarter of last year alone.

    Moreover, the fizzling of the market hasn’t turned into a reason to swear off wearables as an investment opportunity… quite the opposite, actually. It’s just now become considerably clearer what consumers want an

  • [By Paul Ausick]

    Fitbit Inc. (NYSE: FIT) dropped about 3.3% on Thursday to record a new 52-week low of $5.62. The stock closed at $5.81 on Wednesday. Volume was about 35% below the daily average of around 11.6 million shares. The company had no news, but the ripples are still spreading from the charges leveled by competitor Jawbone over Fitbit’s theft of trade secrets.

Top 10 Medical Stocks To Buy Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Biotech stocks have been particularly unloved during the past year, with the iShares Nasdaq Biotech Index ETF (IBB) gaining just 7% to the S&P 500′s 20% rise. Today, however, Amgen (AMGN) is getting a lot of love from the market after releasing Street beating earnings and reporting that its anti-cholesterol drug reduced heart attacks.

  • [By Maxx Chatsko]

    Shares of Radius Health (NASDAQ:RDUS) rose over 20% Monday morning after Amgen (NASDAQ:AMGN) announced worrisome complications were discovered during a phase 3 trial for its osteoporosis drug candidate, Evenity. While the drug candidate met its primary endpoint in a more than 4,000-patient phase 3 study, a high rate of serious heart-related side effects were discovered. The drug was previously expected to gain marketing approval from the U.S. Food and Drug Administration in July, but that decision will now be delayed by up to a year or more, if the drug is approved at all.

  • [By Ben Levisohn]

    Amgen (AMGN) has tumbled 3.6% to $158.65 after beating earnings forecasts but missing on sales.

    Buffalo Wild Wings (BWLD) has dropped 3% to $157.51 after its earnings fell short of the Street consensus.

  • [By WWW.THESTREET.COM]

    Finally on Friday, Tiffany (TIF) reports, and Cramer is betting on positive news now that the company has an activist involved. He was also bullish on Amgen’s (AMGN) analyst meeting, saying investors should use any market weakness earlier in the week to buy.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

  • [By Keith Speights]

    Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren’t high on the list when it came to dividends. Over the past few years, though, Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD) have risen in prominence as attractive alternatives for dividend-seeking investors.

Top 10 Medical Stocks To Buy Right Now: Proteon Therapeutics, Inc.(PRTO)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Proteon Therapeutics Inc (NASDAQ: PRTO) got a boost, shooting up 31 percent to $1.70 after the company disclosed that it has received the FDA Breakthrough Therapy designation for Vonapanitase. Proteon Therapeutics posted a narrower-than-expected quarterly loss.

Top 10 Medical Stocks To Buy Right Now: ePlus Inc.(PLUS)

Advisors’ Opinion:

  • [By Monica Gerson]

    ePlus Inc. (NASDAQ: PLUS) is estimated to post its quarterly earnings at $1.21 per share on revenue of $284.62 million.

    Tilly’s Inc (NYSE: TLYS) is expected to post a quarterly loss at $0.07 per share on revenue of $119.93 million.

Leave a Reply

Your email address will not be published. Required fields are marked *